{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-24-000124","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2024-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.019281+00:00","generated_at":"2026-05-31T23:08:38.279194+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Xeris CEO Paul Edick steps down; John Shannon named CEO; Q2 revenue >$47M (+23% YoY)","bullets":["CEO Paul R. Edick transitions to Senior Advisor effective Aug 1, 2024; John Shannon (President & COO) appointed new CEO and Board member.","Marla S. Persky appointed Chairperson of the Board effective Aug 1, 2024.","Preliminary Q2 2024 total revenue exceeds $47.0M, representing >23% growth over prior year.","Year-end 2024 cash guidance reaffirmed at $55M to $75M."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-24-000124","json":"https://secwatch.observer/filing/0001867096-24-000124.json","markdown":"https://secwatch.observer/filing/0001867096-24-000124.md","text":"https://secwatch.observer/filing/0001867096-24-000124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709624000124/0001867096-24-000124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709624000124/xers-20240707.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:08:38.279194+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4413e8542b","claim":"Paul R. Edick resigned as Chairman of the Board at Xeris Biopharma Holdings, Inc..","evidence_excerpt":"On July 8, 2024, the Company announced that, effective August 1, 2024 (the “Transition Date”), Paul R. Edick will transition from his role as Chief Executive Officer and Chairman of the Board of Directors of the Company (the “Board”) and will become a Senior Advisor to the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709624000124/0001867096-24-000124-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"696a7833ab","claim":"John Shannon was appointed as Class III Director at Xeris Biopharma Holdings, Inc..","evidence_excerpt":"The Board also approved the appointment of Mr. Shannon as a Class III director, effective as of the Transition Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709624000124/0001867096-24-000124-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"},{"claim_id":"9946799c19","claim":"Paul R. Edick resigned as Chief Executive Officer at Xeris Biopharma Holdings, Inc..","evidence_excerpt":"On July 8, 2024, the Company announced that, effective August 1, 2024 (the “Transition Date”), Paul R. Edick will transition from his role as Chief Executive Officer and Chairman of the Board of Directors of the Company (the “Board”) and will become a Senior Advisor to the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709624000124/0001867096-24-000124-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"9ed9676cb8","claim":"Marla S. Persky was appointed as Chairperson of the Board at Xeris Biopharma Holdings, Inc..","evidence_excerpt":"Marla S. Persky, currently a Class III director of the Company, has been appointed by the Board to serve as the Chairperson of the Board, effective as of the Transition Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709624000124/0001867096-24-000124-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairperson of the Board"}],"fact_type":"executive_change"},{"claim_id":"e583f6ab82","claim":"John Shannon was appointed as Chief Executive Officer at Xeris Biopharma Holdings, Inc..","evidence_excerpt":"John Shannon, currently the Company’s President and Chief Operating Officer, has been appointed by the Board to serve as the Company’s Chief Executive Officer, effective as of the Transition Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709624000124/0001867096-24-000124-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}